Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
|Videos|May 5, 2022
Study reveals 20-year data on inflatable penile prostheses
Author(s)Urology Times staff
“For the first time, we have 20-year follow-up data after the penile prosthesis,” says Mohit Khera, MD, MBA, MPH.
Advertisement
In this video, Mohit Khera, MD, MBA, MPH, discusses the background, key findings, and take-home messages from the recent Urology study, “Long-term Survival Rates of Inflatable Penile Prostheses: Systematic Review and Meta-Analysis,” for which he served as a study author. Khera is a professor and the F. Brantley Scott Chair in Urology at Baylor College of Medicine in Houston, Texas.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
SubscribeAdvertisement
Related to this article
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Advertisement
Advertisement